Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 26 (28) 4603-4609
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
TRP
Primary Committee:
Leuk Corr Sci
Sec. Committees:
   
Pharmas:
 
Grants:
CA16058, CA101140, CA77658, CA114725, CA31946  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-8525, CALGB-8765, CALGB-8461, CALGB-9665
Phases:
3, N/A
Keywords:
Hematologic Malignancies